Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumors

Neoplasia

Volumn 9, Issue 3, 2007, Pages 181-183

  Dalai, Irene ^a   Missiaglia, Edoardo ^a   Barbi, Stefano ^a   Butturini, Giovanni ^a   Doglioni, Claudio ^b   Falconi, Massimo ^a   Scarpa, Aldo ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

ARHI; Pancreatic endocrine tumor; Survival; Time to progression; Tumor differentiation

Indexed keywords

RAS HOMOLOGUE MEMBER 1; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOCRINE TUMOR; GENE EXPRESSION; HUMAN; HUMAN TISSUE; OUTCOME ASSESSMENT; PANCREAS TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

EID: 33947357718     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06838     Document Type: Article

References (11)

1. Kloppel G, Perren A, and Heitz PU (2004). The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014, 13-27.
2. Perren A, Komminoth P, and Heitz PU (2004). Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci 1014, 199-208.
3. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, and Bast RC (2003). ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22, 2897-2909.
4. Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, and Bast RC Jr (2005). Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol 407, 455-468.
5. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, et al. (1999). NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96, 214-219.
6. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, and Bast RC Jr (2004). Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res 10, 6559-6566.
7. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC Jr, et al. (2003). Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 9, 3660-3666.
8. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, Bianchi G, Sica A, Peri G, Melzi R, et al. (2002). Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 51, 55-65.
9. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, Ferdeghini M, Pederzoli P, Scarpa A, and Falconi M (2006). Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 13, 1213-1221.
10. Weber F, Aldred MA, Morrison CD, Plass C, Frilling A, Broelsch CE, Waite KA, and Eng C (2005). Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. J Clin Endocrinol Metab 90, 1149-1155.
11. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, Iacono C, Serio G, and Zamboni G (1996). Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 27, 1124-1134.